Abstracts

Pilot study with Intercept treated buffy coat derived platelet concentrates
Presented at: 22nd Congress of the Society of French Transfusion Sanguine (SFTS) 2005, 6/27/05 - 6/30/05

Background: Platelet concentrates (PC) still have a significant risk of transmitting pathogens, mainly bacteria. Pathogen reduction technologies have been devised to reduce this risk to a minimum. Intercept^® (Baxter-Cerus) is a PRT which combine the addition of amotosalen and ultraviolet light illumination. We report here a pilot study where Intercept treated PC were prepared and transfused to patients.

Methods. After removing BC (OptipressII, Baxter)from whole blood donations after centrifugation, by top&bottom method, five ABO identical BC were pooled in additive solution (Intersol® for Intercept and Composol® PS, Fresenius for routine) and separated by centrifugation. PCs were treated with Intercept according to manufacturer instructions.

Results:

	Intercept	Routine
Patients (n)	25	10
Tx. (n)	188	90
Pre-tx plat count	12,3±14.1	14,1±11.5	NS
1 h CCI	10,065 ± 9,394	8,028 ± 6,866	NS
24 h CCI	5,090 ± 6,892	7,959 ± 6,339	0.002
Hours next tx.	70.9 ± 90	87.6 ± 53.8	NS
Platelet yield	3,69	4,21	<0.0005
Days of storage	2,55	3,68	<0.0005
Reactions (%)	1.6	2.2	NS

Conclusion: BC derived PC treated with Intercept produced an immediate transfusion response similar to that observed with routine PC. The 24 h-CCI was lower although the interval between transfusions was not significantly shortened. We did not find a significant relationship between days of storage and 1-, and 24-hours CCI.